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Background/Aims: Endoscopic ultrasound-guided fine 
needle aspiration (EUS-FNA) and Trucut biopsy (TCB) are sen-
sitive techniques for diagnosing mediastinal lesions, but it is 
unclear how either one or both should be used to obtain a 
pathologic diagnosis. The objective of our study was to evalu-
ate whether EUS-TCB impacts the diagnosis of mediastinal 
lesions after the initial on-site review of EUS-FNA specimen 
suggests a suboptimal result. Methods: We enrolled con-
secutive patients with mediastinal lesions who underwent 
EUS-TCB during the same procedure if the initial EUS-FNA 
demonstrated an inadequate FNA sample or suggested that 
histopathology was required for diagnosis. Diagnostic ac-
curacies between procedures were compared as the main 
outcome. Results: Twenty-seven patients (14 men; median 
age, 56 years; range, 19 to 82 years) underwent EUS-FNA 
and EUS-TCB to evaluate a mediastinal lymphadenopathy 
or mass (n=17), to determine the cancer stage (n=3) or to 
exclude tumor recurrence or metastasis (n=7). The overall di-
agnostic accuracies of EUS-FNA and EUS-TCB were 78% and 
67%, respectively (p=0.375). The combined diagnostic accu-
racy of EUS-FNA plus EUS-TCB was 82%. In six patients with 
nondiagnostic EUS-FNA, EUS-TCB provided a final diagnosis 
in one patient (17%). Conclusions: In the current series of 
patients with mediastinal masses or adenopathy, the admin-
istration of EUS-TCB following suboptimal results for the on-
site cytology review did not increase the diagnostic yield. (Gut 
Liver 2013;7:150-156)
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INTRODUCTION
Tissue acquisition from benign and malignant posterior me-
diastinal lymph nodes or masses is necessary to guide manage-
ment. The traditional approaches to sampling of mediastinal 
lesions include: computed tomography (CT)-guided percutane-
ous biopsy, transbronchial fine needle aspiration (FNA), medias-
tinoscopy, mediastinotomy, and thoracoscopy. However, these 
approaches have various limitations of poor tissue yield, ad-
verse safety profile and increased costs.1 Endoscopic ultrasound 
(EUS)-FNA is a sensitive test for the diagnosis of mediastinal 
lesions such as lymphadenopathy of unknown causes, staging 
of nonsmall cell lung cancer or esophageal cancer, and evalu-
ation of benign conditions such as sarcoidosis.2-4 Although the 
diagnostic accuracy of EUS-FNA is generally high, it has several 
limitations such as the variable availability of on-site cytol-
ogy assessment and the acquisition of only a cellular specimen 
for evaluation.5,6 Interpretation of cytologic specimens may be 
difficult due to obscuring blood, necrotic material, and inflam-
matory cells. Furthermore, inadequate cytologic specimens may 
preclude performance of immunostains required to classify tu-
mors such as lymphomas and mesenchymal tumors.7
Since its introduction in 2002, EUS-guided Trucut biopsy 
(EUS-TCB) has attempted to overcome the limitations of EUS-
FNA by acquisition of histology specimens which permit evalu-
ation of tissue architecture and use of immunohistochemistry 
(IHC) when necessary. Nevertheless, the role of EUS-TCB for 
sampling of various lesions remains debatable. Criticisms of 
EUS-TCB include difficult maneuverability due to needle rigidity 
and spring-loaded mechanism, increased cost, uncertain safety, 
and paucity of clinical data to develop practice guidelines.
Studies comparing the diagnostic yield of EUS-FNA to EUS-
TCB have shown that TCB is at least as accurate as FNA and 
Cho CM, et al: Rescue EUS-TCB Following EUS-FNA  151
the supplementary value of EUS-TCB to EUS-FNA remains con-
troversial.8-17 There are little data evaluating the impact of ad-
ditional histology obtained with TCB following an inconclusive, 
unknown or unevaluated FNA result. One study evaluating the 
additional value of EUS-TCB to EUS-FNA in patients with me-
diastinal lesions demonstrated that the diagnostic yield of both 
procedures was comparable and authors recommended limiting 
the use of EUS-TCB to specific cases in which EUS-FNA is not 
conclusive.12 However, there are no data on the impact of res-
cue EUS-TCB for mediastinal lesions after the results of on-site 
cytology review of EUS-FNA are inconclusive. In the current 
study, we aim to evaluate the diagnostic impact of EUS-TCB in 
mediastinal lesions after initial on-site review of EUS-FNA sug-
gests a suboptimal cytology specimen.
MATERIALS AND METHODS
1. Study population and design
This study was approved by the Institutional Review Board 
at Indiana University Medical Center. Utilizing a prospectively 
updated EUS database, we identified all patients from Novem-
ber 2005 through July 2010 who underwent EUS-TCB of any 
mediastinal lymph node or mass. EUS-TCB was considered in 
a lesion measuring at least 18 mm in maximal diameter (size 
of histology tray on the needle) when 1) on-site cytopathology 
review of initial EUS-FNA was nondiagnostic or hypocellular; 
or 2) histopathology was deemed to be helpful by the cytopa-
thologist or endoscopist (i.e., suspected lymphoma, well differ-
entiated carcinoma, mesenchymal tumors, or lesions requiring 
immunostaining) to confirm the final diagnosis. The anatomical 
position of the lesion was based on the American Thoracic So-
ciety mediastinal station system18 using a combination of prior 
imaging including CT or magnetic resonance imaging and the 
final results of EUS.
The following data were abstracted from medical records and 
our prospectively updated EUS database: prior radiographic 
data, subject demographics, EUS examination results (including 
sites biopsied by EUS-TCB or EUS-FNA, number of needle pass-
es, results of cytology and histology, and immunochemistry if 
performed), procedural complications, requirement for any other 
diagnostic procedures after EUS, and postprocedure follow-up 
data. The EUS characteristics of the lesion biopsied included: 
long axis diameter, shape, homogeneity, echogenicity, margins, 
and presence of invasion were also recorded. When surgery was 
performed, the type of surgery, surgical margins, final histopa-
thology and immunostain (if available) of the primary tumor, 
and lymph nodes or metastatic sites were noted. When avail-
able, surgical histopathology was considered the final diagnosis 
for each patient. In the absence of surgery, results of EUS-FNA 
or EUS-TCB and clinical follow-up were considered the refer-
ence standard for diagnosis.
2. EUS procedures and specimen processing
After written informed consent was obtained, the study par-
ticipants received conscious sedation with various combinations 
of intravenous midazolam, meperidine, fentanyl, or propofol 
under appropriate cardiorespiratory monitoring. All procedures 
were performed by one among five experienced endosonogra-
phers, each of whom had performed more than 2,000 proce-
dures before the commencement of this study.
In some patients, EUS was initially performed with a radial 
echoendoscope (GFUM-130, GF-UM160, or GF-UE160; Olympus 
America Inc., Center Valley, PA, USA). EUS-FNA was performed 
in the standard fashion using a curvilinear array echoendoscope 
(GF-UC140P-AL5; Olympus America Inc.). Under EUS guid-
ance, each lesion was aspirated by a 22-gauge EUS-FNA needle 
(EchoTip; Cook Medical Inc., Winston-Salem, NC, USA). Doppler 
color ultrasonography was used to ensure the absence of inter-
vening vascular structures along the anticipated needle path. 
The FNA needle was passed through the largest diameter pos-
sible in each lesion to maximize tissue sampling. Manual suc-
tion was applied to the FNA needle with a 10 mL syringe for the 
first pass. If a bloody specimen was encountered with the first 
pass, suction pressure was reduced or eliminated in some cases 
at the discretion of the pathologist and endoscopist. Each aspi-
rate was placed on glass slides, and both air-dried and alcohol-
fixed smears were prepared. The remaining material was then 
flushed from the needle and collected for subsequent prepara-
tion of a cell block. Air-dried smears were stained with Diff-
Quik method for on-site review and to assess for the need for 
additional passes for review or immunostaining. An attending 
cytopathologist was present on-site for immediate slide review 
and to determine the adequacy of the specimens and provide a 
preliminary diagnosis when possible. Alcohol-fixed smears were 
later stained by Papanicolaou method and reviewed by one or 
more cytopathologists. Immunocytochemistry from cytology 
specimens was later performed selectively at the discretion of 
the pathology department based on results from a combination 
of initial on-site cytology review, cellularity of obtained cell 
block and results and adequacy of histology from core biopsy. 
Depending on the discretion of on-site cytopathologist, 1 to 2 
additional passes were made and placed into a cell block prepa-
ration. In patients with suspected lymphoma based on clinical 
information, material was obtained for flow cytometry.
If on-site review indicated a nondiagnostic (no viable tumor 
cells), hypocellular (tumor cells present but of insufficient qual-
ity for definitive diagnosis) or bloody specimen or when tissue 
architecture was sought, then EUS-TCB was performed. Patients 
in whom EUS-TCB was performed comprised the study popula-
tion. At least two EUS-FNA passes were made prior to consider-
ation of EUS-TCB.
Core biopsy was obtained using a 19-gauge EUS-TCB needle 
(Quick-Core; Cook Medical Inc.). The biopsy device was initially 
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placed in the firing position by the endoscopy assistant and the 
needle assembly was advanced through the accessory channel 
of the endoscope. Before advancing the Trucut needle into the 
lesion, the projected path was interrogated with power Dop-
pler to ensure the absence of intervening blood vessels. After 
the needle was inserted into the tumor, the instrument tip was 
straightened; the tissue tray was fired into the tumor completely, 
so that the longest possible fragment was obtained.
EUS-TCB was repeated until one or more visible cores were 
obtained. Immediate touch preps were not performed. The core 
biopsy specimen was placed into formalin and processed later 
with hematoxylin and eosin (H&E) stain for histopathologic 
analysis. IHC was attempted whenever this aided the diagnosis.
 Per department policy, all patients were called 24 to 72 hours 
after EUS procedure to assess short-term complications. At each 
call, each subject was asked specially about any change in base-
line abdominal pain, symptoms of GI bleeding, sore throat, or 
visits to other health care facilities for any treatment related to 
the endoscopy.
3. Cytological and histological analysis
Histologic and cytologic samples were reviewed by various 
attending pathologists for adequacy and diagnosis. Inadequate 
specimens were defined as tissue samples that contained no rep-
resentative or useful tissue to render a pathologic diagnosis. The 
gold standard for the final diagnosis included surgical resection 
when available or the results of patients’ history, FNA+TCB, and 
a clinical follow-up for at least 6 months with repeated imag-
ing to assess for disease progression. In the absence of surgi-
cal resection, a diagnostic biopsy from either TCB or FNA for 
a specific malignancy (i.e., lymphoma) or benign disease (i.e., 
sarcoidosis) was utilized as a gold standard for comparison to 
the other biopsy technique. Patients with a diagnosis of benign 
lymphadenopathy were confirmed by clinical follow-up and im-
aging tests to ensure that no malignancy developed. In patients 
with final diagnosis of lymphoma, the diagnosis was accepted if 
monoclonal proliferation of lymphoid cells was proved by flow 
cytometry/immunostaining or histological core biopsy on EUS. 
Atypical or abnormal cells were considered a nondiagnostic re-
sult. Other results were considered satisfactory for nonoperative 
diagnosis as follows: diagnostic morphology or immunostains 
when required for mesenchymal and solid tumors; noncaseating 
granulomas for sarcoidosis; identification of organism for infec-
tion; epithelial lining for benign cyst. For calculation of diag-
nostic yield (final diagnosis established by EUS-FNA, EUS-TCB, 
or combination of the techniques), inadequate biopsy specimens 
were considered as nondiagnostic.
4. Statistical analysis
For analysis, continuous variables were expressed as means 
with standard deviations or medians with ranges, and dichoto-
mous or categorical variables were expressed as simple propor-
tions with or without 95% confidence limits. Student’s t-test 
and chi-square or Fisher’s exact tests were used to test for dif-
ferences in comparisons between continuous and dichotomous 
variables, respectively. The comparison of the diagnostic yields 
between the two techniques according to each other in which 
they were performed was assessed using the McNemar test. The 
mean number of needle passes between the two techniques 
was compared using the paired t-test. Statistical analyses were 
performed by using SPSS version 12.0 (SPSS Inc., Chicago, IL, 
USA). A p-value of 0.05 or less was considered as indicating 
statistical significance.
RESULTS
1. Study population
Between November 2005 and July 2010, a total of 30 patients 
(14 men; median age, 56 years; range, 19 to 82 years) under-
went both EUS-FNA and EUS-TCB for 31 mediastinal lesions. 
One lesion was excluded due to loss of TCB sampling tissue dur-
ing pathologic processing. On-site cytology evaluation for FNA 
specimen was not performed in three cases and these were ex-
cluded from data analysis. The indications for the 27 procedures 
were to evaluate mediastinal lymphadenopathy or mass in 17 
(63%), to determine cancer stage in three (11%), and to exclude 
tumor recurrence or metastasis in seven (26%). Biopsy speci-
mens were taken from lymph nodes or masses in the subcarinal 
region in 18, paraesophageal lesion in two, and one each in 
retrotracheal region, lower paratracheal region, aortopulmonary 
window, middle mediastinum and distal esophageal wall. In two 
with lymphadenopathy, the site of biopsy was not specified.
The mean size of lesions biopsied was 40±19 mm. The me-
dian number of needle passes performed was greater with EUS-
FNA (four passes; range, 2 to 8) compared to EUS-TCB (three 
passes; range, 1 to 10) (p=0.046). Grossly visible core tissue by 
EUS-TCB was obtained in 23 sites (85%). No endoscopic com-
plications were noted.
2. Diagnosis by EUS-FNA and EUS-TCB
Among 27 patients who underwent EUS-guided biopsy, the 
final clinical diagnosis (malignant in 13 and benign in 14) (Table 
1) was established by surgery in four, EUS-guided biopsies +/- 
flow cytometry or immunostaining in 16, EUS imaging in one, 
and clinical and imaging follow-up in six. EUS-FNA +/- EUS-
TCB established the diagnosis in 22 (82%). In the remaining 
five, the final diagnosis was confirmed by EUS image in one 
(bronchogenic cyst), serologic test and clinical follow-up in one 
(histoplasmosis) and other invasive procedures including cervi-
cal lymph node excision, mediastinoscopy, and thoracotomy in 
three (lymphoma).
EUS-FNA was technically feasible in all sites. The diagnos-
tic yield of cytology from EUS-FNA was 78% (21/27). Among 
diagnostic FNA specimens, immunocytochemical studies were 
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performed for further characterization of the primary tumor in 
four and flow cytometry for evaluation of possible lymphoma 
were also done in four. Of these, immunocytochemistry con-
tributed to the final diagnosis of gastrointestinal stromal tumor 
(GIST) in one patient and lymphoma in another. EUS-TCB was 
technically feasible in all attempted biopsies. Overall, diagnostic 
histology was obtained for 18 (67%) patients which was similar 
to the yield of diagnostic cytology from EUS-FNA (p=0.375). 
Among specimens with a visible core of tissue (median length, 
4 mm; range, 1 to 15 mm), the diagnostic accuracy was 74% 
(17/23). Two of seven histology specimens (one each of a GIST 
and malignant glomus tumor) sent for immunohistochemical 
study contributed to the final diagnosis. A visible core tissue 
was obtained in six of nine nondiagnostic EUS-TCB specimens. 
However, these six did not contribute to obtaining a final diag-
nosis because of insufficient specimen for immunohistochemical 
study in three and H&E stain in one, acquisition of normal gut 
wall in one, and necrotic tissue only in one, Combined diagnos-
tic accuracy of EUS-FNA and EUS-TCB was 82% (22/27), which 
is similar to EUS-FNA alone (p=1.0) but superior to EUS-TCB 
alone (p=0.125), that is statistically not significant.
Comparison of the number of needle passes for each of the 
four subgroups by diagnostic contribution (Table 2) showed that 
the subgroup with diagnostic FNA and TCB had fewer needle 
passes performed with EUS-TCB (three passes; range, 1 to 8) 
compared to EUS-FNA (four passes; range, 2 to 8; p=0.046).
Table 1. Results of EUS-FNA and EUS-TCB by Final Diagnosis in 27 Patients
Site Size, mm EUS-TCB core tissue Final diagnosis
FNA diagnostic/TCB diagnostic
Subcarinal 90 Visible Melanoma
Subcarinal 30 Visible SCLC
Paraesophageal 90 Visible Malignant glomus tumor
Subcarinal 23 Visible NSCLC
Inferior mediastinal 42 Visible Germ cell tumor
Site not specified 68 Visible RCC
Lower esophagus 50 Visible GIST
Subcarinal 55 Visible Histoplasmosis
Subcarinal 20 Visible Sarcoidosis
Subcarinal 31 Visible Sarcoidosis
Subcarinal 33 Visible Sarcoidosis
Retrotracheal 18 Visible Sarcoidosis
Subcarinal 40 Poor Sarcoidosis
Subcarinal 26 Visible Sarcoidosis
Subcarinal 32 Visible Benign reactive lymph node
Subcarinal 23 Visible Benign reactive lymph node
AP window 45 Visible Mediastinal abscess
FNA diagnostic/TCB nondiagnostic
Subcarinal 45 Visible NSCLC
Subcarinal 25 Visible Lymphoma
Subcarinal 63 Visible Benign reactive lymph node
Subcarinal 30 Poor Benign reactive lymph node
FNA nondiagnostic/TCB diagnostic
Lower paratracheal 40 Visible Sarcoidosis
FNA nondiagnostic/TCB nondiagnostic
Subcarinal 30 Visible Lymphoma
Subcarinal 26 Poor Lymphoma
Subcarinal 40 Visible Lymphoma
Paraesophageal 28 Poor Bronchogenic cyst
Site not specified 50 Visible Histoplasmosis
EUS-FNA, endoscopic ultrasound-guided fine needle aspiration; EUS-TCB, endoscopic ultrasound-guided Trucut biopsy; SCLC, small cell lung 
cancer; NSCLC, nonsmall cell lung cancer; RCC, renal cell carcinoma; GIST, gastrointestinal stromal tumor; AP, aortopulmonary.
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DISCUSSION
EUS-FNA is a well-established technique in diagnosing lymph 
nodes and masses of the posterior mediastinum, obtaining 
samples for cytological examinations either as a primary diag-
nostic procedure or in cases where other biopsy techniques have 
failed.19 It can be safely performed with an overall diagnostic 
accuracy of 60% to 90%, depending on the site and availability 
of on-site cytopathologist.17,20-22
Certain neoplasms such as lymphomas, well-differentiated 
cancers and stromal tumors are often difficult to diagnose by 
cytological assessment alone. TCB can overcome the limitations 
of EUS-FNA by providing histologic samples. Since the intro-
duction of EUS-TCB in 2002, there has been continuous debate 
as to the need and role of EUS-TCB and its use has varied con-
siderably among institutions.6
Our study shows that the diagnostic accuracy of EUS-TCB 
for mediastinal lesions is equivalent to an initially suspected 
suboptimal EUS-FNA specimen of the same lesion. These find-
ings are similar to other studies (Table 3).8-17 This relatively high 
cytology yield in our study was somewhat surprising given the 
requirement for preliminary nondiagnostic or suboptimal cytol-
ogy review. This highlights the limitations of on-site cytology 
review of air-dried specimens for determination of specimen 
adequacy. Previous studies have suggested that the combined 
techniques are superior to either one alone.13,15 However, Berger 
et al.12 showed no significant difference in the diagnostic ac-
curacy among EUS-FNA, EUS-TCB, and the combination. We 
found that the combined diagnostic accuracy of EUS-FNA and 
EUS-TCB was equal to EUS-FNA alone but higher than EUS-
TCB alone. For malignant intra-abdominal lesions, EUS-FNA 
has a slightly higher accuracy than TCB and a combined ap-
proach may be helpful.
One of the factors limiting the performance of TCB is a tech-
nical one related to the difficulty in inserting and firing the 
needle when the endoscope is in an angulated position (e.g., in 
the duodenum and gastric fundus). This is rarely a problem in 
the esophagus as the scope is in a straight position and in the 
current study TCB was successfully carried out in all patients. 
Nevertheless, a visible core biopsy sample was not procured in 
four. In our study the diagnostic accuracy of EUS-FNA was be-
low 90%. The reason for a lower EUS-FNA diagnostic accuracy 
(78%) than previously reported in the literature (over 90%) was 
likely due to several factors, including a significant percent-
age of patients with benign diseases (52%) where cytology is 
frequently limited, and our definition of diagnostic accuracy. 
Therefore, until more data is available, we recommend the use 
of EUS-FNA with on-site cytopathology. Rescue EUS-TCB for 
mediastinal lesions may then be considered with a small incre-
mental diagnostic yield.
An alternative to the current approach of performing FNA 
first followed by TCB has been performed in a prospective study 
with 30 patients.17 In this trial, FNA was used as a rescue proce-
Table 2. Comparison of Needle Passes According to the Diagnostic 
Contribution of FNA and TCB
Subgroup No. of FNA pass No. of TCB pass p-value
FNA+/TCB+ (n=17) 4 (3–8) 3 (1–8) 0.046
FNA+/TCB- (n=4) 4.5 (2–8) 2.5 (2–3) 0.229
FNA-/TCB+ (n=1) 10 5 NA
FNA-/TCB- (n=5) 3 (2–5) 3 (2–3) 0.477
Data are presented as median (range).
FNA, fine needle aspiration; TCB, Trucut biopsy; NA, not available.
Table 3. Published Results for the Comparison of Diagnostic Accuracy between EUS-FNA and EUS-TCB
Author
No. of needle passes Overall diagnostic accuracy
FNA TCB p-value FNA, % TCB, % p-value
Dewitt et al. (2011) (n=38)8 4 (1–7) 3 (1–8) NA 76 79 NA
Gerke et al. (2010) (n=80)9 Not stated 3 (1–8) NA 77.8 88.3 0.24
Fernández-Esparrach et al. (2010) (n=40)10 1.9 2.1 NS 52 55 NS
Berger et al. (2009) (n=70)12 3.0 3.0 NS 93 90 NS
Sakamoto et al. (2009) (n=24)11 Not stated Not stated NA 91.7 (25 G)
79.7 (22 G)
54.1 <0.05
Storch et al. (2008) (n=48)13* 5.8 (2–8) 4.1 (1–6) <0.001 79 79 NS
Saftoiu et al. (2007) (n=30)14 1.8 2 NS 73.7 68.4 NS
Wittmann et al. (2006) (n=159)15† 3 (1–6) 2 (1–4) NA 77 73 NA
Varadarajulu et al. (2004) (n=18)16 6.5 2.5 <0.04 89 78 NS
Levy et al. (2003) (n=20)17 3.3 (1–10) 2 (1–4) <0.05 85 60 NS
EUS-FNA, endoscopic ultrasound-guided fine needle aspiration; EUS-TCB, endoscopic ultrasound-guided Trucut biopsy; NA, not available; NS, 
not significant.
*The combined accuracy of both FNA and TCB was 98% (p=0.007 vs EUS-TCB); †91% (p=0.008 vs EUS-TCB).
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dure to TCB if touch prep in the room revealed benign disease 
(nondiagnostic) or if Trucut failed to obtain a core specimen. 
Although this approach is novel, it still requires on-site review 
of a touch prep specimen similar as performed during on-site 
cytology review and would not avoid occasional failures to 
obtain a tissue core. A recent prospective cohort study using a 
newly developed 19-gauge EUS-guided core biopsy device (Pro-
Core; Cook Medical Inc.) reported that 102 (89%) of the 114 in-
tramural or extramural lesions biopsied were able to be assessed 
histologically with a sensitivity and specificity of 90% and 
100%, respectively.23 Further studies of this needle are needed to 
confirm these promising findings.
The current study represents the first description of the impact 
of rescue EUS-TCB for mediastinal lesions after inconclusive on-
site cytology review of EUS-FNA specimens. Nevertheless, there 
are several limitations that merit discussion. First, a variety of 
mediastinal sites and lesions were sampled for this study which 
limits potential application of our results to any particular ana-
tomical station or region. Second, the use of EUS-TCB only in 
patients with suspected nondiagnostic/hypocellular specimens 
of on-site review limits its utility to these patients. Finally, our 
retrospective design and the lack of matched subgroup cohorts 
(with respect to lesion types and number of patients included in 
each of the four subgroups in Table 1) raise potential bias.
In conclusion, our findings show no additional impact of 
EUS-TCB on the accuracy of EUS-FNA for the diagnosis of 
mediastinal lesions. The combined diagnostic accuracy of EUS-
FNA plus EUS-TCB is numerically but not statistically higher 
compared to FNA alone or TCB alone. Thus, EUS-FNA with on-
site cytology review should be considered the primary method 
for obtaining tissue from mediastinal lesions. EUS-TCB may 
supplement a suboptimal result of EUS-FNA for these lesions.
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